We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of a feline cutaneous mast cell tumour using imatinib mesylate as a neoadjuvant tyrosine kinase inhibitor therapeutic agent.
- Authors
JOONYOUNG KIM; HA-JUNG KIM
- Abstract
A two-year-old spayed female American shorthair cat presented with a rough, circular, exophytic mass on the genital area. The clinical findings and histopathological examination revealed that the mass contained neoplastic mast cells and, thus, was diagnosed as a mast cell tumour. The anatomical location of the mass was not easily accessible for surgical intervention. We administered a targeted therapy using oral imatinib mesylate for eight weeks to reduce the size of the lesion and to facilitate the successful surgical removal. The tumour mass eventually reduced by 21% and was surgically excised. This is possibly the first study to use imatinib mesylate as a tumour reduction neoadjuvant to therapeutically address a feline cutaneous mast cell tumour located in a surgically inaccessible part of the body.
- Subjects
PROTEIN-tyrosine kinase inhibitors; MAST cells; PROTEIN-tyrosine kinases; KINASE inhibitors; TUMORS
- Publication
Veterinární Medicína, 2020, Vol 65, Issue 9, p84
- ISSN
0375-8427
- Publication type
Article
- DOI
10.17221/91/2019-VETMED